Biotechnology

AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1

AstraZeneca reported Q1 2026 total revenue of $15.3bn, up 8% at constant exchange rates, as oncology and rare disease offset CVRM declines.

Iran's Use of Foreign Militias Signals Strain on Regime Stability

Iran's regime's dependency on foreign militias indicates a decrease in likely protests. Current market odds show 7.5% chance of regime change.

Exploring the Transformative Potential of GLP-1 Medicines and Their Impact on Public Health

GLP-1 medicines are set to exceed $100 billion in revenue, signaling a major revolution in public health and investment opportunities.

Exploring Genetic Influence and Ethical Considerations in Reproductive Technology

This article discusses genetic influence on traits, the ethical aspects of embryo selection, and the societal impact of genetics.

Advancements in Genetic Testing: Transforming Prenatal Care and Cancer Detection

Genetic testing advancement enhances prenatal care and cancer detection, showcasing innovation that improves healthcare diagnostics.

Exploring Bittensor and Its Impact on Drug Discovery

Bittensor is revolutionizing drug discovery through decentralized networks, cutting costs and streamlining processes for innovative solutions.

Exploring the Future of Longevity and Brain-Computer Interfaces

Exploring advancements in longevity, brain-computer interfaces, and vision restoration technologies shaping the future of healthcare.

Revolutionizing Chemical Manufacturing with Enzymatic Processes

Solugen innovates chemical manufacturing by combining biology and chemistry for efficiency, transforming production methods and challenging traditional beliefs.

Revolutionizing Aging: The Future of Age Reversal Research

Recent research indicates the possibility of reversing aging, paving the way for extended lifespans and groundbreaking health advancements.

Roche's Strategic AI Investment Revolutionizes Drug Development

Roche's deployment of 3,500 Nvidia GPUs demonstrates a bold move to enhance drug development through AI, targeting key therapeutic markets.

Alto Neuroscience Secures $120 Million for Depression Treatment Development

Alto Neuroscience raises $120 million to advance ALTO-207, a treatment for resistant depression, boosting investor confidence.

Thrive Capital Raises $10 Billion for Innovative Investments

Thrive Capital's new fund exceeds $10 billion, targeting investments in AI, robotics, and life sciences, marking a major growth initiative.

Microsoft and Bristol Myers Squibb Partner to Enhance Lung Cancer Detection

Microsoft partners with Bristol Myers Squibb to use AI for early lung cancer detection, targeting underserved areas for better healthcare access.

NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Transform Drug Discovery

NVIDIA and Lilly are launching an AI lab to redefine drug discovery, with a commitment of up to $1B over five years.

3D Systems Secures FDA Clearance Amid Financial Pressures